Table of contents
November 2003 Vol 2 No 11
In this issue
p847 | doi:10.1038/nrd1241
Editorial: Taming the double-edged sword
p849 | doi:10.1038/nrd1248
News and Analysis
News
Why are clinical costs so high?
p851 | doi:10.1038/nrd1250
News
News
European initiative to provide Africa with control of therapeutic development
p853 | doi:10.1038/nrd1249
Patent watch
Breach of implied contract
p854 | doi:10.1038/nrd1234
Patent watch
BMS wins lawsuit over CTLA4 patents
p854 | doi:10.1038/nrd1235
Patent watch
Canada to allow production of generic AIDS drugs
p854 | doi:10.1038/nrd1237
From the analyst's couch
Biologics for psoriasis
p855 | doi:10.1038/nrd1231
Fresh from the Pipeline
Atazanavir sulphate
p857 | doi:10.1038/nrd1232
Research Highlights
Bioterrorism: Paralyzing the two-faced BOTOX
p859 | doi:10.1038/nrd1233
Stroke: Piecing together a picture of stroke
p860 | doi:10.1038/nrd1240
High-throughput screening: Screen test
p860 | doi:10.1038/nrd1243
Chemical genetics: Knowledge = power
p861 | doi:10.1038/nrd1236
Gpcrs: A solid view of GPCRs
p862 | doi:10.1038/nrd1238
In brief
Anticancer Drugs | Computational Chemistry | Proteolysis | Cardiovascular Disease
p862 | doi:10.1038/nrd1239
Reviews
Therapeutic angiogenesis in cardiovascular disease
Michael Simons & J. Anthony Ware
p863 | doi:10.1038/nrd1226
Targeting the Nogo Receptor to Treat Central Nervous System Injuries
Daniel H. S. Lee, Stephen M. Strittmatter & Dinah W. Y. Sah
p872 | doi:10.1038/nrd1228
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
Garret A. FitzGerald
p879 | doi:10.1038/nrd1225
Ace revisited: A new target for structure-based drug design
K. Ravi Acharya, Edward D. Sturrock, James F. Riordan & Mario R. W. Ehlers
p891 | doi:10.1038/nrd1227
New targets for allergic rhinitis — a disease of civilization
Stephen T. Holgate & David Broide
p903 | doi:10.1038/nrd1224
Perspectives
Opinion
Challenges and opportunities in animal drug development: a regulatory perspective
Claire M. Lathers
p915 | doi:10.1038/nrd1229
Science and society
Virtual drug discovery and development for neglected diseases through public–private partnerships
Solomon Nwaka & Robert G. Ridley
p919 | doi:10.1038/nrd1230
Careers and Recruitment
The search for new global health entrepreneurs
Hannah E. Kettler
p931 | doi:10.1038/nrd1247
